Shenzhen Hepalink Pharmaceutical Group News

DBS: Maintains a 'Market Perform' rating on Hepalink (09989) with a target price lowered to HKD 3.5.

Zhitong FinanceSep 17 11:36

Damo: Maintaining Hypry's (09989) “In sync with the market” rating, the target price was reduced to HK$3.9

Zhitong FinanceFeb 20 09:56

Hypertherm (002399): Heparin preparations and CDMO revenue increased 22% and 33% year-on-year, driving a 30% increase in the company's performance

方正證券Mar 30, 2023 19:37

Goldman Sachs: Maintains Hepry's (09989) “neutral” rating target price to HK$8.96

Zhitong FinanceFeb 2, 2023 10:06

Hypertherm (002399) Quarterly Review Report: Pharmaceutical Exports Continue to Grow, API Business Disrupted by Overseas

國聯證券Oct 30, 2022 00:00

Hypertherm (002399): Performance growth driven by cost improvements and export volume

國聯證券Oct 11, 2022 00:00

Hypertherm (002399): Heparin formulation revenue increased 42% year-on-year, helping the company achieve a spectacular 51% increase in the company's performance

方正證券Aug 30, 2022 00:00

Hypertherm (002399) 2022 Interim Report Review: Performance Meets Expectations, All Pipeline Businesses Maintain Excellent Growth

東吳證券Aug 29, 2022 00:00

Hypertherm (002399): Heparin, the global leader in heparin, widens short-term spreads and actively broadens the field of macromolecular CDMO+ innovative drugs in the long term

東吳證券Jun 9, 2022 00:00

Hypertherm (002399): Heparin preparations are growing steadily, and overall performance is in line with expectations

西南證券Apr 30, 2022 00:00

Hypertherm (002399): Overall performance is in line with expectations, an inflection point in the API business

西南證券May 13, 2021 00:00

Hypertherm (002399): Transfer of 8.66% of the shares of KYMAB, a participating biopharmaceutical company, and investment in new drugs is gradually entering a harvest period

安信證券Jan 12, 2021 00:00

Hypertherm (002399): Transfer of KYMAB shares continues to focus on the main business

中信證券Jan 12, 2021 00:00

Hypri (002399) three Quarterly report 2020 comments: the overall performance is in line with the expected steady growth of the preparation business

西南證券Nov 6, 2020 00:00

Comments on the three-quarter report of Hypree (002399): the global layout of preparations promotes the value of the whole industry chain.

長城證券Nov 3, 2020 00:00

Heypree (002399) Quarterly report 2020 comments: Q3 is dragged down by API business CDMO and innovative drugs waiting to blossom

中信證券Nov 2, 2020 00:00

Hepri (002399): heparin API affected by customer purchase rhythm 2020Q3 performance growth slows down

安信證券Oct 30, 2020 00:00

Hypree (002399) dynamic Review: enoxaparin Sodium FDA approved to accelerate Global layout

長城證券Sep 22, 2020 00:00

Hypree (002399): enoxaparin's approval in the United States is expected to increase its share in the regulatory market.

西南證券Sep 22, 2020 00:00

Hypertherm (002399) in-depth follow-up report: the US heparin reserve tender will reach Hepalin Reserve's clear advantage

中信證券Sep 16, 2020 00:00